Skip to content

Arterial Closure Device Comparison Trial II - ACDC Trial II

A Randomized Trial of Angioseal and Starclose for Hemostasis After PCI

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00428155
Enrollment
448
Registered
2007-01-29
Start date
2007-01-31
Completion date
Unknown
Last updated
2007-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Arterial Hemostasis After Coronary Intervention

Keywords

hemostasis, angioplasty, stenting, closure device, angioseal, starclose

Brief summary

PCI (coronary angioplasty) is a procedure performed through a catheter to open up blockages in the coronary arteries using balloons and stents for the treatment of angina or myocardial infarction. The balloon catheters and stents are moved to the coronary arteries through a sheath (a small tube used for placing of balloon and stent catheters in the body) placed in a major artery passing through the groin. After the PCI procedure and the removal of sheath, an arterial closure device is commonly placed to stop bleeding and allow you to get out of bed sooner. Although the usefulness of closure devices has been documented before their approval by the regulatory authorities, it is unclear if one device is better compared to other commercially available devices. The purpose of the study is to compare the two approved arterial closure devices, Angioseal and Starclose. This study will help us identify the better of the two devices to improve patient comfort after the procedure.

Detailed description

All patients scheduled to undergo percutaneous coronary interventions will be screened for inclusion into the study. Informed consent will be obtained and patients will be randomized to the placement of either Angioseal or a Starclose vascular closure device to achieve hemostasis after the PCI procedure. The randomization will take place after a femoral angiogram has confirmed the suitability of the femoral artery for placement of arterial closure device. All patients will be monitored for bleeding or hematoma formation for twelve hours after the procedure. Patients will be ambulated at two hours after placement of the arterial closure device. A complete blood count and a vascular ultrasound will be performed in all patients before discharge to assess blood loss and detect vascular complications such as hematoma, arteriovenous fistula or femoral artery pseudoaneurysm. A written quality of life survey will be completed before discharge and at four weeks. A nursing survey will be completed by the nursing staff to determine nurse-sensitive outcomes and nurse resource utilization.

Interventions

DEVICEclosure device placement

Sponsors

Unity Health Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
25 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients undergoing non emergent PCI procedures with a 6F arterial sheath. * Femoral artery anatomy favorable for the placement of an arterial closure device.

Exclusion criteria

* Emergency PCI * End stage renal disease * Prior arterial closure device use within 90 days. * Symptomatic peripheral vascular disease. * Arterial puncture of the superficial femoral artery. * Suspected double wall puncture (puncture of anterior & posterior wall of femoral artery). * Placement of intra aortic balloon pump. * Placement of a femoral venous sheath.

Design outcomes

Primary

MeasureTime frame
A composite of major vascular complications defined as device failure, bleeding, large hematoma, local infection etc.

Secondary

MeasureTime frame
post procedural myocardial infarction
30 day incidence of death, MI, TVR
Patient discomfort
Quality of life measurements at discharge and four weeks
Minor vascular complication (minor bleeding, analgesic use)
Time to hemostasis
Lack of ambulation per protocol
Need for additional measures to achieve hemostasis (manual pressure, femostop use, etc.)
Nurse resource utilization at discharge

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026